Deutsche Bank Reports Teleflex (TFX) Downgrade and $251.0 Target; Pharmerica (PMC)’s Sentiment Is 1.32

November 14, 2017 - By Richard Conner

Among 10 analysts covering Teleflex (NYSE:TFX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Teleflex has $295.0 highest and $145 lowest target. $232.89’s average target is -8.15%

below currents $253.55 stock price. Teleflex had 27 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, March 7 by Needham. The firm has “Buy” rating given on Friday, February 26 by Brean Capital. The stock of Teleflex Incorporated (NYSE:TFX) has “Equal-Weight” rating given on Friday, November 3 by Morgan Stanley. The firm has “Buy” rating by Barclays Capital given on Monday, June 26. On Friday, July 31 the stock rating was maintained by Brean Capital with “Buy”. The firm has “Buy” rating given on Friday, November 3 by Needham. Leerink Swann upgraded the stock to “Outperform” rating in Friday, September 8 report. The company was upgraded on Friday, January 6 by Jefferies. The company was maintained on Thursday, June 8 by Leerink Swann. The stock of Teleflex Incorporated (NYSE:TFX) earned “Buy” rating by Needham on Friday, August 4.

PharMerica Corporation is an institutional pharmacy services company. The company has market cap of $907.18 million. The Firm services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. It has a 48.04 P/E ratio.

Since June 1, 2017, it had 0 insider purchases, and 2 insider sales for $554,159 activity. $514,173 worth of Teleflex Incorporated (NYSE:TFX) was sold by RANDLE STUART A on Wednesday, June 7. 200 Teleflex Incorporated (NYSE:TFX) shares with value of $39,986 were sold by Klasko Stephen K. M.D..

Investors sentiment decreased to 0.99 in 2017 Q2. Its down 0.08, from 1.07 in 2017Q1. It worsened, as 39 investors sold Teleflex Incorporated shares while 120 reduced holdings. 47 funds opened positions while 110 raised stakes. 40.61 million shares or 1.10% less from 41.06 million shares in 2017Q1 were reported. Nomura Asset Limited stated it has 0.04% of its portfolio in Teleflex Incorporated (NYSE:TFX). Eaton Vance reported 83,216 shares. Parthenon Lc invested in 0.63% or 12,650 shares. Oppenheimer Asset Inc holds 2,388 shares or 0.01% of its portfolio. Dekabank Deutsche Girozentrale invested 0.01% of its portfolio in Teleflex Incorporated (NYSE:TFX). The New York-based Mufg Americas Corp has invested 0.01% in Teleflex Incorporated (NYSE:TFX). Ardevora Asset Mngmt Limited Liability Partnership holds 1.15% or 175,300 shares. Rodgers Brothers, Pennsylvania-based fund reported 4,151 shares. Federated Investors Pa holds 0.02% of its portfolio in Teleflex Incorporated (NYSE:TFX) for 38,160 shares. Bryn Mawr Tru has 40,570 shares. Legal & General Plc has invested 0.01% in Teleflex Incorporated (NYSE:TFX). Eagle Asset Mgmt Inc holds 0.03% in Teleflex Incorporated (NYSE:TFX) or 23,325 shares. Manufacturers Life Insur The reported 66,443 shares. Suntrust Banks stated it has 10,312 shares. Arizona State Retirement Sys holds 0.07% or 24,501 shares in its portfolio.

About 100 shares traded. Teleflex Incorporated (NYSE:TFX) has risen 24.36% since November 14, 2016 and is uptrending. It has outperformed by 7.66% the S&P500.

Analysts await Teleflex Incorporated (NYSE:TFX) to report earnings on February, 22. They expect $2.40 EPS, up 12.68% or $0.27 from last year’s $2.13 per share. TFX’s profit will be $109.52 million for 26.41 P/E if the $2.40 EPS becomes a reality. After $2.12 actual EPS reported by Teleflex Incorporated for the previous quarter, Wall Street now forecasts 13.21% EPS growth.

Teleflex Incorporated is a provider of medical technology products. The company has market cap of $11.57 billion. The Firm designs, develops, makes and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. It has a 46.41 P/E ratio. The Firm operates through six divisions: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa ; Asia, and Original Equipment Manufacturer (OEM).

Sessa Capital Im L.P. holds 1.68% of its portfolio in PharMerica Corporation for 511,436 shares. Smith Graham & Co. Investment Advisors Lp owns 403,049 shares or 1.15% of their US portfolio. Moreover, Phocas Financial Corp. has 0.74% invested in the company for 273,788 shares. The California-based Fuller & Thaler Asset Management Inc. has invested 0.33% in the stock. Nuveen Asset Management Llc, a Illinois-based fund reported 1.08 million shares.

Analysts await PharMerica Corporation (NYSE:PMC) to report earnings on February, 23. They expect $0.52 earnings per share, down 10.34% or $0.06 from last year’s $0.58 per share. PMC’s profit will be $16.18M for 14.01 P/E if the $0.52 EPS becomes a reality. After $0.46 actual earnings per share reported by PharMerica Corporation for the previous quarter, Wall Street now forecasts 13.04% EPS growth.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>